Resumen
Background Pulmonary arterial hypertension (PAH) is a severe disease characterized by elevated blood pressure
in the pulmonary artery that can ultimately damage the right ventricle of the heart. PAH is pathophysiologically
heterogeneous, which makes early diagnosis and treatment difficult. Inflammation is thought to be an important
factor in the development and progression of this disease and may explain some of the observed interindividual
differences. In the context of both acute and chronic inflammation, neutrophil recruitment to the lung has
been suggested as a potential biomarker for studying PAH progression. However, there are currently no specific
probes for its non-invasive in vivo detection. The imaging-based gold standard for assessing inflammation is [18F]
fluorodeoxyglucose (18F-FDG), which is not cell specific. This highlights the urgent need for more specific molecular
probes to support personalized medicine.
Methods This study investigated the potential of magnetic nanoradiotracers based on ultrasmall iron oxide
nanoparticles, functionalized with N-cinnamoyl-F-(D)L-F-(D)L-F peptide, to detect increased neutrophil infiltration
in vivo in different PAH animal models via positron emission tomography. These nanoprobes target formyl peptide
receptor 1, which is abundantly expressed in the cell membrane of neutrophils. To assess the benefit of these
nanoprobes, their biodistribution was first assessed via magnetic resonance imaging and histology. Then, their lung
uptake was compared by positron emission tomography with that of 18F-FDG in two types of PAH animal models with
different profiles of inflammation and neutrophil infiltration: monocrotaline and double-hit Sugen-chronic hypoxia
PAH rat models.
Results Our targeted magnetic nanoradiotracer detected an increase in pulmonary neutrophil infiltration in both
PAH models and distinguished between them, which was not possible with 18F-FDG PET.
Conclusions This study underscores the importance of targeted imaging in providing an individualized and
longitudinal evaluation of heterogeneous and multifactorial diseases such as PAH. The use of targeted multimoda